🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsDosing & ProtocolsDe-escalation protocols — January 2024

De-escalation protocols — January 2024

KevinCompounds Tue, Jan 27, 2026 at 11:37 PM 6 replies 838 viewsPage 1 of 2
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Jan 27, 2026 at 11:37 PM#1

I titrated faster than the label because I felt fine, hit a wall at the third step, and had to come back down — which I now think was the predictable outcome rather than bad luck.

The arithmetic in one line: half-life about a week, so steady state at four to five weeks, so a four-week interval is one steady state per step. Two-week intervals mean every step is dosed onto a rising curve.

The bit I cannot resolve on my own is what the trials actually did with participants who could not tolerate a step, because that is the situation I am in and the protocol summaries skip it.

I have searched first, so if this is covered somewhere point me at it and I will read it.

23 18jennifer_SEA, tyler_CSCS, VanRx_Mike and 20 others
Reply Quote Save Share Report
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Jan 27, 2026 at 11:44 PM#2

Taking the question as asked, rather than the general version of it. The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks later. The end point of the ladder is set by tolerability, not by a schedule, and there is no evidence that reaching the top faster produces a better outcome.

I would rather be corrected than agreed with, if it comes to it.

Last edited: Jan 28, 2026 at 3:44 AM
22 17dave_SLC, FDA_TrackerJim, ricardo_MIA and 19 others
Reply Quote Save Share Report
FDA_TrackerJim
Senior Member
1,567
7,890
Feb 2024
Rockville, MD
Jan 27, 2026 at 11:51 PM#3
PeptideChemSF said:
The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks…

That is right for the weekly injectables. For the daily agents the interval logic is different and the four-week convention does not transfer.

21 16MikeNYC_runner and 18 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
BiostatsBrad
Member
456
2,345
Jul 2024
Durham, NC
Jan 27, 2026 at 11:58 PM#4
KevinCompounds said:
I titrated faster than the label because I felt fine, hit a wall at the third step, and had to come back down — which I now think was the predictable…

Can confirm the pattern KevinCompounds describes. Four weeks is the pharmacokinetics, not caution. With a one-week half-life you need four to five half-lives to reach steady state, so at two weeks you are dosing on top of a concentration that has not finished rising. Escalating then stacks exposure and you get the side-effect burden of the higher dose before you have seen the benefit of the current one.

20 15james_edin, FranDenver, Dr.BariatricHTX and 17 others
Reply Quote Save Share Report
DeniseRN_TPA
Member
345
1,567
Aug 2024
Tampa, FL
Jan 28, 2026 at 12:33 AM#5

Clinical perspective, offered as context rather than as advice.

Dose escalation anxiety for titration: I was terrified to move from 0.5mg to 1.0mg based on horror stories in this forum. But my actual experience? Slightly more appetite suppression, zero additional side effects.

Remember that the people posting about terrible side effects are a biased sample. Most people titrate up without drama — they just don't post about it because it's uneventful.

Last edited: Jan 28, 2026 at 3:33 AM
19 14Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 16 others
Reply Quote Save Share Report

Similar Threads

Micro-dosing semaglutide — is sub-therapeutic dosing effective?16 replies
Injection technique: subcutaneous depot formation and absorption8 replies
Semaglutide PK modeling — when to time your injection12 replies
Reconstitution calculator — compounded peptide dosing math7 replies
Half-life implications for missed doses — PK-based guidance5 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register